|
|
Blood, 1 June 2005, Vol. 105, No. 11, pp. 4235-4246.
Prepublished online as a Blood First Edition Paper on February 15, 2005; DOI 10.1182/blood-2004-11-4535.
Previous Article | Table of Contents | Next Article 
GENE THERAPY
Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis
Ute Modlich,
Olga S. Kustikova,
Manfred Schmidt,
Cornelia Rudolph,
Johann Meyer,
Zhixiong Li,
Kenji Kamino,
Nils von Neuhoff,
Brigitte Schlegelberger,
Klaus Kuehlcke,
Kevin D. Bunting,
Sonja Schmidt,
Annette Deichmann,
Christof von Kalle,
Boris Fehse, and
Christopher Baum
From the Department of Hematology, Hemostaseology and Oncology, and the Institute of Cellular and Molecular Pathology, Hannover Medical School, Germany; Bone Marrow Transplantation, University Hospital Eppendorf, Hamburg, Germany; University Hospital, Albert-Ludwig University, Freiburg, Germany; EUFETS AG, Idar-Oberstein, Germany; the Division of Hematology/Oncology and Center for Stem Cell and Regenerative Medicine, Case Western Reserve University, Cleveland, OH; and the Division of Experimental Hematology, Cincinnati Children's Hospital Medical Center, OH.
Previous studies have demonstrated leukemic complications in mice after high-copy retroviral gene transfer of the multidrug resistance 1 (MDR1) cDNA, encoding a membrane-located efflux pump expressed in hematopoietic stem cells. In contrast, no such complications or MDR1-associated alterations of hematopoiesis were observed in numerous other studies exploring MDR1 gene transfer into cell lines, mice, dogs, nonhuman primates, and human subjects. Here, we show that leukemias associated with retroviral expression of MDR1 depend on high vector dose, and involve the selection of clones with combinatorial insertional mutagenesis of proto-oncogenes or other signaling genes. Compared with insertion patterns in normal long-term repopulating hematopoietic cells, such hits were overrepresented in leukemic clones, pointing to a causal role. A similar constellation of insertion sites was also observed in a leukemia arising after high-copy retroviral gene transfer of a fluorescent protein. Spectral karyotyping demonstrated additional chromosomal translocations in a subset of cases, indicative of secondary genetic instability. We also show that insertional mutants can be amplified in vitro prior to transplantation. On the basis of these findings, we suggest the use of preclinical dose-escalation studies to define a therapeutic index for retroviral transgene delivery.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
Y.-J. Kim, Y.-S. Kim, A. Larochelle, G. Renaud, T. G. Wolfsberg, R. Adler, R. E. Donahue, P. Hematti, B.-K. Hong, J. Roayaei, et al.
Sustained high-level polyclonal hematopoietic marking and transgene expression 4 years after autologous transplantation of rhesus macaques with SIV lentiviral vector-transduced CD34+ cells
Blood,
May 28, 2009;
113(22):
5434 - 5443.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Ramezani, T. S. Hawley, and R. G. Hawley
Combinatorial Incorporation of Enhancer-Blocking Components of the Chicken {beta}-Globin 5'HS4 and Human T-Cell Receptor {alpha}/{delta} BEAD-1 Insulators in Self-Inactivating Retroviral Vectors Reduces Their Genotoxic Potential
Stem Cells,
December 1, 2008;
26(12):
3257 - 3266.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Watanabe-Okochi, J. Kitaura, R. Ono, H. Harada, Y. Harada, Y. Komeno, H. Nakajima, T. Nosaka, T. Inaba, and T. Kitamura
AML1 mutations induced MDS and MDS/AML in a mouse BMT model
Blood,
April 15, 2008;
111(8):
4297 - 4308.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Ahmed, N. Arseni, H. Glimm, W. Hiddemann, C. Buske, and M. Feuring-Buske
Constitutive Expression of the ATP-Binding Cassette Transporter ABCG2 Enhances the Growth Potential of Early Human Hematopoietic Progenitors
Stem Cells,
March 1, 2008;
26(3):
810 - 818.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Bozorgmehr, S. Laufs, S. E. Sellers, I. Roeder, W. J. Zeller, C. E. Dunbar, and S. Fruehauf
No Evidence of Clonal Dominance in Primates up to 4 Years Following Transplantation of Multidrug Resistance 1 Retrovirally Transduced Long-Term Repopulating Cells
Stem Cells,
October 1, 2007;
25(10):
2610 - 2618.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. R. Ball, I. H. Pilz, M. Schmidt, S. Fessler, D. A. Williams, C. von Kalle, and H. Glimm
Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression
Blood,
September 15, 2007;
110(6):
1779 - 1787.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Zhang, S. I. Thornhill, S. J. Howe, M. Ulaganathan, A. Schambach, J. Sinclair, C. Kinnon, H. B. Gaspar, M. Antoniou, and A. J. Thrasher
Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells
Blood,
September 1, 2007;
110(5):
1448 - 1457.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. S. Kustikova, H. Geiger, Z. Li, M. H. Brugman, S. M. Chambers, C. A. Shaw, K. Pike-Overzet, D. d. Ridder, F. J. T. Staal, G. v. Keudell, et al.
Retroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways
Blood,
March 1, 2007;
109(5):
1897 - 1907.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. E. Dunbar
The Yin and Yang of Stem Cell Gene Therapy: Insights into Hematopoiesis, Leukemogenesis, and Gene Therapy Safety
Hematology,
January 1, 2007;
2007(1):
460 - 465.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. Modlich, J. Bohne, M. Schmidt, C. von Kalle, S. Knoss, A. Schambach, and C. Baum
Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity
Blood,
October 15, 2006;
108(8):
2545 - 2553.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Shou, Z. Ma, T. Lu, and B. P. Sorrentino
Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy
PNAS,
August 1, 2006;
103(31):
11730 - 11735.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Neff, B. C. Beard, and H.-P. Kiem
Survival of the fittest: in vivo selection and stem cell gene therapy
Blood,
March 1, 2006;
107(5):
1751 - 1760.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Lagresle-Peyrou, F. Yates, M. Malassis-Seris, C. Hue, E. Morillon, A. Garrigue, A. Liu, P. Hajdari, D. Stockholm, O. Danos, et al.
Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity
Blood,
January 1, 2006;
107(1):
63 - 72.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Du, S. E. Spence, N. A. Jenkins, and N. G. Copeland
Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis
Blood,
October 1, 2005;
106(7):
2498 - 2505.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Deisseroth
Normal and pathological functions of mammalian retroelements
PNAS,
August 30, 2005;
102(35):
12292 - 12293.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Kustikova, B. Fehse, U. Modlich, M. Yang, J. Dullmann, K. Kamino, N. von Neuhoff, B. Schlegelberger, Z. Li, and C. Baum
Clonal Dominance of Hematopoietic Stem Cells Triggered by Retroviral Gene Marking
Science,
May 20, 2005;
308(5725):
1171 - 1174.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|